Both human and salmon CT have been approved for treatment of bone disorders including Paget’s disease and osteoporosis, however, they have distinct binding kinetics, affinity and efficacy [9], [10], [11] that impact on G protein recruitment and activation [11], suggesting different modes of interaction with CTRs. This evidence concerns the gene CALCA and bone disorder.